The selective PTGES inhibitor CAY10526 and agonist of EP2 receptor Evatanepag, which are crucial elements in AA metabolic pathway, were also used, and the chemosensitivity of osteosarcoma cells to lobaplatin was markedly reduced and elevated, respectively. This evidence concerns the gene PTGES and osteosarcoma.